Last Updated: November 16, 2026

CLINICAL TRIALS PROFILE FOR LY3549492

« Back to Dashboard


Clinical Trials for LY3549492

Trial ID Title Status Sponsor Phase Summary
NCT04758234 ↗ A Study of LY3549492 in Healthy Participants Recruiting Eli Lilly and Company Phase 1 The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in healthy participants. The blood tests will be performed to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study includes two parts and will last up to approximately 76 days for each participant, including screening.
NCT05327595 ↗ A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM) Not yet recruiting Eli Lilly and Company Phase 1 The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in participants with T2DM. Blood tests will be done to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study has two parts. Each participant will enroll in only one part. The study will last either 12 or 13 weeks, depending on part.
NCT06194500 ↗ A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants Completed Eli Lilly and Company Phase 1 The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will be conducted in healthy males and has two parts. In Part A, participants will receive carbon-14 (14C) radiolabeled LY3549492 ([14C] LY3549492) given by mouth. In Part B, participants will receive LY3549492 by mouth. Three hours later, participants will receive [14C] LY3549492 given into a vein. The radioactive substance C14 will be incorporated into the study drug to investigate the study drug and breakdown products to find out how much of these passes from blood into urine, stool, and breath. The study will last about 2 months in Part A and about 1½ months in Part B. This includes screening, treatment, and follow-up visits.
NCT06683508 ↗ A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight ACTIVE_NOT_RECRUITING Eli Lilly and Company PHASE2 The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.
NCT06869018 ↗ A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants RECRUITING Eli Lilly and Company PHASE1 The purpose of this study is to evaluate how well LY3549492 is tolerated and what side effects may occur in Japanese participants with Type 2 Diabetes Mellitus (T2D) and healthy Japanese participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3549492 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 19 weeks for both Part A (Cohorts 1-3) for multiple-ascending doses (MAD), and Part B (Cohorts 4-5) multiple-ascending doses (MAD), for a total of approximately 25 weeks, including screening.
NCT07030868 ↗ A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes TERMINATED Eli Lilly and Company PHASE2 The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight with type 2 diabetes. Participation in the study will last about 11 months.
NCT07073170 ↗ A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus NOT_YET_RECRUITING Eli Lilly and Company PHASE1 The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for LY3549492

Condition Name

Condition Name
Intervention Trials
Healthy 4
Obesity 3
Overweight 3
Type 2 Diabetes 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH
Intervention Trials
Diabetes Mellitus, Type 2 4
Overweight 3
Obesity 3
Diabetes Mellitus 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LY3549492

Trials by Country

Trials by Country
Location Trials
United States 51
Argentina 2
Japan 1
Canada 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State
Location Trials
Texas 4
Florida 4
California 3
Arizona 3
Illinois 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LY3549492

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase Trials
PHASE2 3
PHASE1 3
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase Trials
Recruiting 3
TERMINATED 2
ACTIVE_NOT_RECRUITING 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LY3549492

Sponsor Name

Sponsor Name
Sponsor Trials
Eli Lilly and Company 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type
Sponsor Trials
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.